https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-27 / Cell. Immunol. 2009;259(1):13-20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-27 / Cell. Immunol. 2009;259(1):13-202009-05-27 00:00:002020-01-08 10:10:17Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-14 / J. Theor. Biol. 2009 Aug;259(4):820-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-14 / J. Theor. Biol. 2009 Aug;259(4):820-72009-05-14 00:00:002019-02-15 08:44:16On immunotherapies and cancer vaccination protocols: a mathematical modelling approach
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-14 / Cancer Sci. 2009 Aug;100(8):1502-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-14 / Cancer Sci. 2009 Aug;100(8):1502-92009-05-14 00:00:002019-02-15 08:52:02Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-07 / J. Clin. Immunol. 2009 Sep;29(5):657-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-07 / J. Clin. Immunol. 2009 Sep;29(5):657-642009-05-07 00:00:002019-02-15 08:49:27Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-05 / Clin. Cancer Res. 2009 May;15(10):3366-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-05 / Clin. Cancer Res. 2009 May;15(10):3366-752009-05-05 00:00:002019-02-15 08:49:28Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Expert Opin Biol Ther 2009 May;9(5):539-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Expert Opin Biol Ther 2009 May;9(5):539-642009-05-01 00:00:002019-02-15 08:44:25Dendritic cells: therapy and imaging
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Hum. Immunol. 2009 May;70(5):331-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Hum. Immunol. 2009 May;70(5):331-92009-05-01 00:00:002019-02-15 09:19:12Melanoma vaccines: The problems of local immunosuppression
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Cancer Invest. 2009 May;27(4):361-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Cancer Invest. 2009 May;27(4):361-82009-05-01 00:00:002019-02-15 08:50:14Tumor vaccines for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Prostate 2009 May;69(6):571-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Prostate 2009 May;69(6):571-842009-05-01 00:00:002019-02-15 08:53:02Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / J. Immunother. 2009 May;32(4):333-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / J. Immunother. 2009 May;32(4):333-402009-05-01 00:00:002019-02-15 08:48:40Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma
